Rationale for New American Diabetes Association guidelines: Are National Cholesterol Education Program goals adequate for the patient with diabetes mellitus?

American Journal of Cardiology

Volumn 96, Issue 4 SUPPL., 2005, Pages 33-36

  Haffner, Steven ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; EDUCATION PROGRAM; GLUCOSE TOLERANCE; HEALTH CARE ORGANIZATION; HUMAN; INCIDENCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

EID: 23744510366     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.05.012     Document Type: Conference Paper

References (14)

1. American Diabetes Association Dyslipidemia management in adults with diabetes Diabetes Care 27 suppl 1 2004 S68 S71
2. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
3. S.M. Grundy, J.I. Cleeman, C.N. Merz, H.B. Brewer Jr, L.T. Clark, D.B. Hunninghake, R.C. Pasternak, S.C. Smith Jr, N.J. Stone National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, and American Heart Association Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
4. W.B. Kannel Diabetes and cardiovascular disease the Framingham Study JAMA 241 1979 2035 2038
5. S.M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, M. Laakso Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 1998 229 234
6. R.C. Turner, H. Millns, H.A. Neil, I.M. Stratton, S.E. Manley, D.R. Matthews, R.R. Holman Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) BMJ 316 1998 823 828
7. S.M. Haffner, M.P. Stern, H.P. Hazuda, B.D. Mitchell, J.K. Patterson Cardiovascular risk factors in confirmed pre-diabetic individuals does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 263 1990 2893 2898
8. F.B. Hu, M.J. Stampfer, S.M. Haffner, C.G. Solomon, W.C. Willett, J.E. Manson Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes Diabetes Care 25 2002 1129 1134
9. S.M. Haffner, C.M. Alexander, T.J. Cook, S.J. Boccuzzi, T.A. Musliner, T.R. Pedersen, J. Kjekshus, K. Pyorala Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels subgroup analyses in the Scandinavian Simvastatin Survival Study Arch Intern Med 159 1999 2661 2667
10. R.B. Goldberg, M.J. Mellies, F.M. Sacks, L.A. Moye, B.V. Howard, W.J. Howard, B.R. Davis, T.G. Cole, M.A. Pfeffer, E. Braunwald CARE Investigators Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels subgroup analyses in the Cholesterol and Recurrent Events trial Circulation 98 1998 2513 2519
11. Heart Protection Study Collaboration Group MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes a randomised placebo-controlled trial Lancet 361 2003 2005 2016
12. H. Colhoun, D.J. Betteridge, P.N. Durrington, G.A. Hitman, H.A. Neil, S.J. Livingstone, M.J. Thomason, M.I. Mackness, V. Charlton-Menys, J.H. Fuller CARDS investigators Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS) multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
13. C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, R. Belder, S.V. Joyal, K.A. Hill, M.A. Pfeffer, A.M. Skene Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
14. J.C. LaRosa, S.M. Grundy, D.D. Waters, C. Shear, P. Barter, J.-C. Fruchart, A.M. Gotto, H. Greten, J.J.P. Kastelein, J. Shepherd, N.K. Wenger Treating for New Targets (TNT) investigators Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435